Lung Cancer News

Having been exposed to benzene during work heightened the odds for lung cancer development, according to results published in American Journal of Respiratory and Critical Care Medicine.

In a study of patients with small cell lung cancer and idiopathic pulmonary fibrosis receiving carboplatin, etoposide and nintedanib, the primary endpoint was met, according to results published in Annals of the American Thoracic Society.

A universal screening and opt-out referral strategy may reduce disparities in tobacco treatment access and increase use of smoking cessation services by people with cancer, according to results of a qualitative improvement study.

Among patients with moderate-risk peripheral lung nodules, a robotic bronchoscopy system had high diagnostic yield, according to results published in Respirology.

CHICAGO — Updated survival data from the randomized phase 3 IMpower010 continued to support adjuvant atezolizumab for patients with stage II to stage IIIA PD-L1-expressing non-small cell lung cancer, according to researchers.

About 40% of cancer cases and nearly half of cancer deaths among U.S. adults aged 30 years or older can be attributable to modifiable risk factors, according to a study led by American Cancer Society researchers.

SAN DIEGO — Six months before dying, patients with COPD and idiopathic pulmonary fibrosis vs. lung cancer had reduced odds for outpatient palliative care, according to a poster at the American Thoracic Society International Conference.

Tiragolumab plus atezolizumab added to chemotherapy did not extend survival outcomes as first-line therapy of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, interim results from a randomized study showed.

SAN DIEGO — Smokers who used electronic cigarettes after quitting had more risk for lung cancer than those who quit but did not use e-cigarettes, according to a study presented at the American Thoracic Society International Conference.

Individuals with laryngeal cancer who stop smoking in the 2- to 4-week window between diagnosis and their first treatment can significantly improve their response to therapy, survival rates and quality of life.